| Rituximab biosimilar (Samsung) |
SAIT-101 |
Phase 3 Clinical |
Samsung Biologics Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Arthritis, Rheumatoid; Anemia; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase |
Details
|
| Rituximab biosimilar (Hualan Biological Engineering) |
WBP-263 |
Phase 3 Clinical |
Hualan Genetic Engineering Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
| Rituximab biosimilar (Boehringer Ingelheim) |
BI-695500 |
Phase 3 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Lymphoproliferative Disorders; Philadelphia Chromosome; Pancytopenia; Plasmablastic Lymphoma; Lymphoma, Mantle-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Leukemia, Myelomonocytic, Chronic; Arthritis, Rheumatoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Anemia; Candidiasis, Vulvovaginal; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Lymphoma, B-Cell, Marginal Zone |
Details
|
| Recombinant humanized monoclonal antibody MIL62 |
MIL62 |
Phase 3 Clinical |
Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd |
Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Nephrosis; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Neuromyelitis Optica; Lymphoma, Non-Hodgkin |
Details
|
| Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) |
|
Phase 3 Clinical |
Shanghai Institute Of Biological Products Co Ltd |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| Divozilimab |
BCD-132 |
Phase 3 Clinical |
Biocad |
Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica |
Details
|
| Ocrelizumab biosimilar (CinnaGen) |
|
Phase 3 Clinical |
Cinnagen |
Multiple Sclerosis |
Details
|
| BAT-4406F |
BAT-4406; BAT-4406F |
Phase 3 Clinical |
Bio-Thera Solutions Ltd |
Neuromyelitis Optica |
Details
|
| Rituximab biosimilar (Nanjing Yoko Biomedical) |
GB-241 |
Phase 3 Clinical |
Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd |
Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blast Crisis; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase |
Details
|
| Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) |
|
Phase 3 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
| Ocrelizumab biosimilar (Celltrion) |
CT-P53 |
Phase 3 Clinical |
Celltrion Inc |
Multiple Sclerosis, Relapsing-Remitting |
Details
|
| Iodine 131 tositumomab |
TST/I131-TST |
Phase 3 Clinical |
Glaxosmithkline Plc |
Lymphoma, B-Cell; Leukemia, Lymphoid; Hodgkin Disease; Multiple Myeloma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) |
B-007 |
Phase 3 Clinical |
Shanghai Crosslink Pharmaceutical R & D Co Ltd |
Myasthenia Gravis; Lymphoma, B-Cell; Nephrosis; Glomerulonephritis, Membranous; Lymphoma, Non-Hodgkin; Pemphigus |
Details
|
| Rituximab biosimilar(Shandong New Time Pharmaceutical) |
H-02; F-007 |
Phase 3 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| Imvotamab |
IGM-2323 |
Phase 2 Clinical |
Igm Biosciences Inc |
Lymphoma, B-Cell, Marginal Zone; Myositis; Lupus Erythematosus, Cutaneous; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Arthritis; Lymphoma, Non-Hodgkin |
Details
|
| Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) |
CART-20; CBM-C20.1; CBM-CD20 1 |
Phase 2 Clinical |
Pla General Hospital |
Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic |
Details
|
| BVX20-CD20 antibody (Biocon/Vaccinex) |
BVX-20; BVX20-MAb |
Phase 2 Clinical |
Biocon Ltd, Vaccinex Inc |
Lymphoma, Non-Hodgkin |
Details
|
| Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase 2 Clinical |
Southwest Hospital Chongqing |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) |
|
Phase 2 Clinical |
Fred Hutchinson Cancer Research Center |
Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Rituximab biosimilar (JHL Biotech) |
JHL-1101 |
Phase 2 Clinical |
JHL Biotech |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell |
Details
|
| Zamtocabtagene autoleucel |
MB-CART2019.1 |
Phase 2 Clinical |
Miltenyi Biotec |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| IMM-0306 |
IMC-002; IMM-0306 |
Phase 2 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) |
PBCAR-20A |
Phase 2 Clinical |
Precision Biosciences Inc |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| ELC-301 |
ELC301; ELC-301 |
Phase 2 Clinical |
Elicera Therapeutics AB, Uppsala University |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| MBS-303 |
MBS-303 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| UCART-20x22 |
UCART-20x22 |
Phase 2 Clinical |
Cellectis Sa |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| bbT-369 |
bbT-369 |
Phase 2 Clinical |
Bluebird Bio Inc |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
| GB-261 |
GB-261 |
Phase 2 Clinical |
Genor Biopharma Co Ltd |
Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| CHO-H01 |
CHO-H01 |
Phase 2 Clinical |
Academia Sinica |
Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
| MB-CART19.1 (Miltenyi Biotec) |
|
Phase 2 Clinical |
Miltenyi Biotec |
Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-T |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma |
Details
|
| MRG001 |
MRG-001 |
Phase 2 Clinical |
Shanghai Miracogen Inc |
Motor Neuron Disease; Lymphoma, B-Cell; Hepatitis, Alcoholic; Cytokine Release Syndrome; Respiratory Tract Diseases; Respiratory Distress Syndrome, Adult; Lymphoma, Non-Hodgkin; Respiratory Insufficiency; Amyotrophic Lateral Sclerosis |
Details
|
| IMPT-514 |
IMPT-514 |
Phase 2 Clinical |
ImmPACT Bio USA Inc |
Lupus Nephritis; Lupus Erythematosus, Systemic |
Details
|
| IPH-6501 |
IPH-6501; IPH-65 |
Phase 2 Clinical |
Innate Pharma SA |
Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
| IMPT-314 |
IMPT-314 |
Phase 2 Clinical |
|
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| CD20 monoclonal antibody（The First Affiliated Hospital of Soochow University） |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Soochow University |
Anemia, Aplastic |
Details
|
| CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) |
|
Phase 2 Clinical |
Shanghai Cellular Biopharmaceutical Group Ltd |
Lymphoma, B-Cell |
Details
|
| ALETA-001 |
ALETA-001 |
Phase 2 Clinical |
Aleta BioTherapeutics Inc |
Lymphoma, B-Cell; Leukemia; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin |
Details
|
| Rituximab Biosimilar (Istituto Giannina Gaslini) |
|
Phase 2 Clinical |
Istituto Giannina Gaslini |
Nephrotic Syndrome |
Details
|
| 1-A-46 |
BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 |
Phase 2 Clinical |
Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| ICP-B02 |
CM-355; ICP-B02 |
Phase 2 Clinical |
Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd |
Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Lymphoma, B-Cell |
Details
|
| Prizloncabtagene autoleucel |
C-CAR039; C-CAR-039; C CAR 039; EXP-039 |
Phase 2 Clinical |
Cellular Biomedicine Group Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| EX-103 |
EX-103; EX103 |
Phase 2 Clinical |
Guangzhou Excelmab Inc |
Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) |
|
Phase 2 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma |
Details
|
| Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) |
|
Phase 2 Clinical |
Shanghai Longyao Biological Technology Co Ltd |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| MB-106 |
MB-106 |
Phase 2 Clinical |
Fred Hutchinson Cancer Research Center |
Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30，Shanghai Unicar-Therapy Bio-medicine) |
|
Phase 2 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Pancreatic Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
| CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) |
|
Phase 1 Clinical |
Henan Provincial Cancer Hospital |
Lymphoma, B-Cell |
Details
|
| Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) |
BAT-4306F |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Lymphoma, Non-Hodgkin |
Details
|
| TRS-005 |
TRS-005 |
Phase 1 Clinical |
Zhejiang Teruisi Pharmaceutical Inc |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
| Rituximab biosimilar (International Biotech Center Generium) |
GNR-006 |
Phase 1 Clinical |
International Biotech Center Generium |
Lymphoma, B-Cell |
Details
|
| Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) |
LZM-002 |
Phase 1 Clinical |
Livzon Pharmaceutical Group Inc |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
| MB-CART20.1 (Miltenyi Biotec) |
|
Phase 1 Clinical |
Miltenyi Biotec |
Melanoma |
Details
|
| Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) |
|
Phase 1 Clinical |
Fujian Medical University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center, National Cancer Institute |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| Rituximab biosimilar (Shanghai CP Guojian Pharmaceutical) |
CMAB-304; 304R |
Phase 1 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
| Rituximab biosimilar (Fred Hutchinson Cancer Research Center) |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center |
Lymphoma, Large B-Cell, Diffuse; Multicentric Castleman's Disease (MCD); Burkitt Lymphoma; Sarcoma, Kaposi |
Details
|
| Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) |
LUCAR-20S |
Phase 1 Clinical |
Nanjing Legend Biotechnology Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Bendamustine Hydrochloride/Rituximab |
|
Phase 1 Clinical |
1globe Biomedical Co Ltd |
Lymphoma, B-Cell |
Details
|
| Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) |
B001; B-001; B001A; B001-A; B001C; B001-C |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Multiple Sclerosis; Neuromyelitis Optica; Lymphoma, Non-Hodgkin; Lymphoma |
Details
|
| Rituximab biosimilar (Gedeon Richter) |
RGB-03 |
Phase 1 Clinical |
Gedeon Richter |
Arthritis, Rheumatoid |
Details
|
| CD20-directed CAR-T cell therapy (Tongji Hospital) |
C-CAR066 |
Phase 1 Clinical |
Tongji Hospital, Cellular Biomedicine Group Inc, Shanghai Cellular Biopharmaceutical Group Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
| JS-203 |
JS-203 |
Phase 1 Clinical |
Shanghai Junshi Biological Engineering Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| Dual CD19/CD20 targeting CAR-T therapy(Poseida Therapeutics) |
|
Phase 1 Clinical |
Poseida Therapeutics Inc |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) |
|
Phase 1 Clinical |
Shanghai Longyao Biological Technology Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| KITE-363 |
KITE-363 |
Phase 1 Clinical |
Kite Pharma |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse |
Details
|
| ACE-1831 |
ACE-1831 |
Phase 1 Clinical |
Acepodia Biotech Inc |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) |
|
Phase 1 Clinical |
Uclas Jonsson Comprehensive Cancer Center |
Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| LUCAR-G39P |
LUCAR-G39P |
Phase 1 Clinical |
Nanjing Legend Biotechnology Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
| Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy(Beijing Cancer Hospital) |
LUCAR-20SP |
Phase 1 Clinical |
Beijing Cancer Hospital |
Lymphoma, Non-Hodgkin |
Details
|
| Rituximab biosimilar (Mabscale) |
|
Phase 1 Clinical |
Mabscale LLC |
Arthritis, Rheumatoid |
Details
|
| ASP-2802 |
ASP2802; ASP-2802 |
Phase 1 Clinical |
Astellas Pharma Global Development Inc |
Lymphoma, B-Cell |
Details
|
| JNJ-1493 |
JNJ-1493 |
Phase 1 Clinical |
Xencor Inc |
Hematologic Neoplasms; Lymphoma, B-Cell |
Details
|
| C-CAR168 CAR T-cell therapy (AbelZeta) |
C-CAR168 |
Phase 1 Clinical |
AbelZeta Pharma Inc |
Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Muscular Diseases |
Details
|
| SCTB-35 |
SCTB35; SCTB-35 |
Phase 1 Clinical |
SinoCelltech Ltd |
Lymphoma, B-Cell |
Details
|
| Recombinant human anti-CD20 momoclonal antibody(Shanghai Crosslink Pharma) |
|
Phase 1 Clinical |
Shanghai Crosslink Pharmaceutical R & D Co Ltd |
Myasthenia Gravis; Pemphigus |
Details
|
| Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) |
|
Phase 1 Clinical |
National Cancer Institute |
Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| RO-7121932 |
RO7121932; RO-7121932; RO 7121932; RG-6035 |
Phase 1 Clinical |
Genentech Inc |
Multiple Sclerosis |
Details
|
| TanCART19/20 |
|
Phase 1 Clinical |
Pla General Hospital |
Neuromyelitis Optica |
Details
|
| LCAR-AIO |
LCAR-AIO; VHH CAR-T |
Phase 1 Clinical |
Nanjing Legend Biotechnology Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CAR-20-19-22 |
CAR-20-19-22 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) |
TRS001 |
Phase 1 Clinical |
Zhejiang Teruisi Pharmaceutical Inc |
Lymphoma |
Details
|
| QLP-31907 |
QLP-31907; QLP31907; PSB-202 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| ADI-001 |
ADI-001 |
Phase 1 Clinical |
Regeneron Pharmaceuticals Inc, Adicet Bio Inc |
Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma |
Details
|
| TQB-2825 |
TQB-2825 |
Phase 1 Clinical |
Wuxi Biologics Co Ltd |
Hematologic Neoplasms |
Details
|
| CD19/CD20 CAR-T Cell Therapy (PersonGen) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
|
Details
|
| JMT-601 |
JMT-601 |
Phase 1 Clinical |
Shanghai Jmt-Bio Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
| LY007 |
LY007 |
Phase 1 Clinical |
Shanghai Longyao Biological Technology Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
| Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) |
|
Phase 1 Clinical |
First Affiliated Hospital Of Zhejiang University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| Plamotamab |
XmAb-13676 |
Phase 1 Clinical |
Xencor Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University, Shanghai YaKe Biotechnology Co Ltd |
Hematologic Neoplasms |
Details
|
| Rituximab/Paclitaxel |
AR-160 |
Phase 1 Clinical |
Mayo Clinic |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) |
|
Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Neoplasms |
Details
|
| Rituximab biosimilar(Bioxpress) |
BXT-2336 |
Clinical |
Bioxpress Therapeutics Sa |
Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Rituximab/Bendamustine/Cytarabine |
|
|
Fondazione Italiana Linfomi Onlus |
|
Details
|
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one. 
A-Z
